Effects of Roxithromycin on Quality of Life and Physiological Outcomes in Bronchiectasis

Prince of Songkla University

Status and phase: Completed; Phase 3

Conditions: Quality of Life; Respiratory Function Tests

Treatments: Drug: Roxithromycin 300 MG; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04122040

54-282-14-3-2

Details and patient eligibility

About

roxithormycin 300 mg per day for 12 weeks could improve quality of life and physiological outcomes in bronchiectasis

Full description

A randomized, double blinded, placebo controlled study was conducted to evaluate the effects of a 12-week administration of roxithromycin 300 mg once daily and a 12-week follow-up period in symptomatic stable bronchiectasis

Enrollment: 40 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

minimum 15 year maximum 75 years

Criteria inclusion Criteria:

Symptomatic bronchiectasis Stable clinical bronchiectasis

Exclusion Criteria:

Adverse drug reaction to macrolide Recent exacerbation within 2 weeks History of macrolide therapy within 2 weeks active malignancy and end stage diseases 5. not perform lung function tests Females who were lactating

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

40 participants in 2 patient groups, including a placebo group

roxithromycin

Active Comparator group

Description:

roxithromycin 300 mg oral per day

Treatment:

Drug: Roxithromycin 300 MG

placebo

Placebo Comparator group

Description:

placebo one tablet per day

Treatment:

Drug: Placebo